Top Pharmaceutical Stocks Worth Watching - April 14th

Key Points

• MarketBeat's screener flagged Eli Lilly, AbbVie, Abbott Laboratories, Travere Therapeutics and Novo Nordisk as the five pharmaceutical stocks to watch, citing the highest dollar trading volume among pharma names in recent days.
• The group spans therapeutic areas and business models—Eli Lilly and Novo Nordisk lead in diabetes/obesity drugs (e.g., Mounjaro, Trulicity, Zepbound), AbbVie focuses on immunology and oncology (Humira, Skyrizi, Rinvoq), Abbott emphasizes diagnostics, devices and generics, and Travere targets rare kidney/metabolic diseases (FILSPARI).
• Pharmaceutical shares can deliver significant gains tied to successful drug approvals and patent protection, but they carry high regulatory, clinical-trial and pipeline risk and often move sharply on trial results, regulatory decisions or patent/reimbursement news.

Eli Lilly and Company, AbbVie, Abbott Laboratories, Travere Therapeutics, and Novo Nordisk A/S are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies involved in researching, developing, manufacturing, and selling prescription drugs, biologics, vaccines, and related services. For investors, these stocks offer potential for significant gains tied to successful drug approvals and patent protection but also carry high regulatory, clinical-trial and pipeline risk, with prices often moving sharply on trial results, regulatory decisions, and patent or reimbursement news. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read Our Latest Research Report on LLY

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Read Our Latest Research Report on ABBV

Abbott Laboratories (ABT)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Read Our Latest Research Report on ABT

Travere Therapeutics (TVTX)

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Read Our Latest Research Report on TVTX

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Read Our Latest Research Report on NVO

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.